Bengaluru, March 6 -- The shares of the pharmaceuticals company specializing in developing, manufacturing, and marketing a wide range of pharmaceuticals jumped upto 7 percent upon receiving approval from the USFDA to manufacture Dasatinib tablets in various strengths (20 mg to 140 mg).
Price action
With a market capitalization of Rs. 92,246.50 Crores on Thursday, the shares of Zydus Lifesciences Ltd jumped upto 6.8 percent after making a high of Rs. 947.95 compared to its previous closing price of Rs. 887.55.
What Happened
Zydus Lifesciences engaged in developing, manufacturing, and marketing a wide range of pharmaceuticals has received final approval from the USFDA to manufacture Dasatinib Tablets in various strengths (20 mg to 140 m...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.